S&P 500   3,666.72 (-0.06%)
DOW   29,969.52 (+0.29%)
QQQ   304.28 (+0.14%)
AAPL   122.94 (-0.11%)
MSFT   214.24 (-0.52%)
FB   281.85 (-1.97%)
GOOGL   1,821.84 (-0.17%)
AMZN   3,186.73 (-0.52%)
TSLA   593.38 (+4.32%)
NVDA   535.84 (-1.10%)
BABA   266.91 (+2.14%)
CGC   28.63 (+1.60%)
GE   10.60 (+1.63%)
MU   69.90 (+1.14%)
AMD   92.31 (-1.53%)
T   29.23 (+0.48%)
NIO   45.35 (-5.48%)
F   9.21 (+0.11%)
ACB   11.24 (+2.65%)
NFLX   497.52 (-1.16%)
BA   237.20 (+5.96%)
GILD   60.86 (-0.44%)
DIS   153.24 (-0.24%)
S&P 500   3,666.72 (-0.06%)
DOW   29,969.52 (+0.29%)
QQQ   304.28 (+0.14%)
AAPL   122.94 (-0.11%)
MSFT   214.24 (-0.52%)
FB   281.85 (-1.97%)
GOOGL   1,821.84 (-0.17%)
AMZN   3,186.73 (-0.52%)
TSLA   593.38 (+4.32%)
NVDA   535.84 (-1.10%)
BABA   266.91 (+2.14%)
CGC   28.63 (+1.60%)
GE   10.60 (+1.63%)
MU   69.90 (+1.14%)
AMD   92.31 (-1.53%)
T   29.23 (+0.48%)
NIO   45.35 (-5.48%)
F   9.21 (+0.11%)
ACB   11.24 (+2.65%)
NFLX   497.52 (-1.16%)
BA   237.20 (+5.96%)
GILD   60.86 (-0.44%)
DIS   153.24 (-0.24%)
S&P 500   3,666.72 (-0.06%)
DOW   29,969.52 (+0.29%)
QQQ   304.28 (+0.14%)
AAPL   122.94 (-0.11%)
MSFT   214.24 (-0.52%)
FB   281.85 (-1.97%)
GOOGL   1,821.84 (-0.17%)
AMZN   3,186.73 (-0.52%)
TSLA   593.38 (+4.32%)
NVDA   535.84 (-1.10%)
BABA   266.91 (+2.14%)
CGC   28.63 (+1.60%)
GE   10.60 (+1.63%)
MU   69.90 (+1.14%)
AMD   92.31 (-1.53%)
T   29.23 (+0.48%)
NIO   45.35 (-5.48%)
F   9.21 (+0.11%)
ACB   11.24 (+2.65%)
NFLX   497.52 (-1.16%)
BA   237.20 (+5.96%)
GILD   60.86 (-0.44%)
DIS   153.24 (-0.24%)
S&P 500   3,666.72 (-0.06%)
DOW   29,969.52 (+0.29%)
QQQ   304.28 (+0.14%)
AAPL   122.94 (-0.11%)
MSFT   214.24 (-0.52%)
FB   281.85 (-1.97%)
GOOGL   1,821.84 (-0.17%)
AMZN   3,186.73 (-0.52%)
TSLA   593.38 (+4.32%)
NVDA   535.84 (-1.10%)
BABA   266.91 (+2.14%)
CGC   28.63 (+1.60%)
GE   10.60 (+1.63%)
MU   69.90 (+1.14%)
AMD   92.31 (-1.53%)
T   29.23 (+0.48%)
NIO   45.35 (-5.48%)
F   9.21 (+0.11%)
ACB   11.24 (+2.65%)
NFLX   497.52 (-1.16%)
BA   237.20 (+5.96%)
GILD   60.86 (-0.44%)
DIS   153.24 (-0.24%)
Log in
NASDAQ:PODD

Insulet Stock Forecast, Price & News

$255.54
+0.47 (+0.18 %)
(As of 12/3/2020 04:30 PM ET)
Add
Compare
Today's Range
$253.29
Now: $255.54
$257.63
50-Day Range
$215.97
MA: $249.33
$265.89
52-Week Range
$121.00
Now: $255.54
$269.42
Volume424,325 shs
Average Volume521,116 shs
Market Capitalization$16.85 billion
P/E Ratio912.68
Dividend YieldN/A
Beta0.73
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. Its Omnipod System comprise two devices: a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, and its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, and the Middle East. Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts.
Insulet logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.2Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.35 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:PODD
CUSIP45784P10
Phone978-600-7000
Employees1,350

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$738.20 million
Cash Flow$0.66 per share
Book Value$1.23 per share

Profitability

Net Income$11.60 million

Miscellaneous

Market Cap$16.85 billion
Next Earnings Date2/23/2021 (Estimated)
OptionableOptionable
$255.54
+0.47 (+0.18 %)
(As of 12/3/2020 04:30 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PODD News and Ratings via Email

Sign-up to receive the latest news and ratings for PODD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Insulet (NASDAQ:PODD) Frequently Asked Questions

How has Insulet's stock price been impacted by Coronavirus (COVID-19)?

Insulet's stock was trading at $172.11 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PODD stock has increased by 48.0% and is now trading at $254.75.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Insulet?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 1 sell rating, 10 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Insulet
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Insulet?

Wall Street analysts have given Insulet a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Insulet wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Insulet's next earnings date?

Insulet is scheduled to release its next quarterly earnings announcement on Tuesday, February 23rd 2021.
View our earnings forecast for Insulet
.

How were Insulet's earnings last quarter?

Insulet Co. (NASDAQ:PODD) released its earnings results on Wednesday, November, 4th. The medical instruments supplier reported $0.17 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.08 by $0.09. The medical instruments supplier earned $234 million during the quarter, compared to analyst estimates of $221.73 million. Insulet had a return on equity of 10.96% and a net margin of 2.20%. The firm's quarterly revenue was up 21.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.01 earnings per share.
View Insulet's earnings history
.

What guidance has Insulet issued on next quarter's earnings?

Insulet issued an update on its FY 2020 After-Hours earnings guidance on Wednesday, November, 4th. The company provided EPS guidance of for the period. The company issued revenue guidance of $885.84-893.222 million, compared to the consensus revenue estimate of $874.11 million.

What price target have analysts set for PODD?

18 brokerages have issued 1 year price objectives for Insulet's stock. Their forecasts range from $179.00 to $266.00. On average, they expect Insulet's stock price to reach $235.19 in the next twelve months. This suggests that the stock has a possible downside of 7.7%.
View analysts' price targets for Insulet
.

Who are some of Insulet's key competitors?

What other stocks do shareholders of Insulet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Square (SQ), The Walt Disney (DIS), salesforce.com (CRM), Roku (ROKU) and The Trade Desk (TTD).

Who are Insulet's key executives?

Insulet's management team includes the following people:
  • Ms. Shacey Petrovic, Pres, CEO & Director (Age 46, Pay $1.9M)
  • Mr. Wayde D. McMillan, Exec. VP,CFO & Treasurer (Age 50, Pay $1.18M)
  • Mr. Charles Alpuche, Exec. VP & COO (Age 60, Pay $1.11M)
  • Mr. John Wodick Kapples, Sr. VP, Sec. & Gen. Counsel (Age 60, Pay $752.92k)
  • Mr. Bret Christensen, Exec. VP & Chief Commercial Officer (Age 48, Pay $975.77k)
  • Mr. Michael L. Levitz, Advisor (Age 46, Pay $1.06M)
  • Ms. Lauren Budden, VP, Chief Accounting Officer & Controller
  • Ms. Deborah R. Gordon CPA, VP of Investor Relations
  • Mr. Michael Spears, Sr. VP of Quality and Regulatory Affairs & Compliance (Age 55)
  • Mr. Philip Hildale, Sr. VP of Sales & Customer Care

What is Insulet's stock symbol?

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Who are Insulet's major shareholders?

Insulet's stock is owned by a number of retail and institutional investors. Top institutional shareholders include William Blair Investment Management LLC (1.43%), Federated Hermes Inc. (0.53%), Standard Life Aberdeen plc (0.52%), Charles Schwab Investment Management Inc. (0.49%), KAMES CAPITAL plc (0.45%) and Victory Capital Management Inc. (0.43%). Company insiders that own Insulet stock include Aiman Abdel-Malek, Bret Christensen, Charles Alpuche, Corinne H Nevinny, David A Lemoine, David Colleran, Eric Benjamin, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic.
View institutional ownership trends for Insulet
.

Which institutional investors are selling Insulet stock?

PODD stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., First Trust Advisors LP, Wasatch Advisors Inc., Commerce Bank, Perceptive Advisors LLC, WINTON GROUP Ltd, Trexquant Investment LP, and ClariVest Asset Management LLC. Company insiders that have sold Insulet company stock in the last year include Bret Christensen, Charles Alpuche, Corinne H Nevinny, David A Lemoine, Eric Benjamin, John A Fallon, Michael P Spears, and Shacey Petrovic.
View insider buying and selling activity for Insulet
.

Which institutional investors are buying Insulet stock?

PODD stock was purchased by a variety of institutional investors in the last quarter, including Great West Life Assurance Co. Can, Jennison Associates LLC, Parian Global Management LP, Standard Life Aberdeen plc, British Airways Pensions Investment Management Ltd, AXA S.A., William Blair Investment Management LLC, and Employees Retirement System of Texas.
View insider buying and selling activity for Insulet
.

How do I buy shares of Insulet?

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Insulet's stock price today?

One share of PODD stock can currently be purchased for approximately $254.75.

How big of a company is Insulet?

Insulet has a market capitalization of $16.80 billion and generates $738.20 million in revenue each year. The medical instruments supplier earns $11.60 million in net income (profit) each year or $0.19 on an earnings per share basis. Insulet employs 1,350 workers across the globe.

What is Insulet's official website?

The official website for Insulet is www.insulet.com.

How can I contact Insulet?

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]

This page was last updated on 12/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.